Medical/Pharmaceuticals
Asieris and CDC Sign Investigational Product Supply Agreement for APL-1202 in Free-Living Amoeba Infections Treatment under Expanded Access Investigational New Drug Program
SHANGHAI, Jan. 6, 2025 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a leading global biopharmaceutical company dedicated to advancing innovative therapies for genitourinary tumors and women's health with significant unmet medical needs, announced the signing of an investigatio...
2025-01-06 18:05
2046
Chime Biologics and Mabgeek Achieve MG-K10 PPQ Milestone, Advancing Atopic Dermatitis and Asthma Therapies Antibody Drug MG-K10 Late-Stage Clinical Trials and Commercialization
* Process Performance Qualification (PPQ) validates robust manufacturing standards and is crucial for regulatory compliance * Marks a key step forward for the world's first once-monthly IL-4Rα-targeting antibody therapeutic for Th2-driven diseases, with a strategic focus on entering the Ameri...
2025-01-03 21:15
5088
GRIT Bio Appoints Jie Jia, Ph.D., as Chief Operating Officer
SHENZHEN, China, Jan. 3, 2025 /PRNewswire/ -- Shenzhen GRIT Biotechnology Co., Ltd., a leading company in cell therapy globally, today announced the appointment ofJie Jia, Ph.D., as Chief Operating Officer (COO), effective on the date of this press release. Dr. Jia, Jie brings over 20 years of...
2025-01-03 15:30
3248
Nona Biosciences Announces Update on Its Collaborator DualityBio's Antibody-Drug Conjugate (ADC) Collaboration with BeiGene
CAMBRIDGE, Mass., Jan. 3, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), today announced that BeiGene. Ltd. has exercised its exclusive option to acquire global development, manufacturing, and commercialization right...
2025-01-03 13:30
2382
Hanx Biopharmaceuticals, Ltd. Announces First Patient Dosing in First-in-Human Phase 1 Clinical Trial of HX044
WUHAN, China, Jan. 2, 2025 /PRNewswire/ -- Hanx Biopharmaceuticals, CO. Ltd, an innovative biotechnology company developing next-generation immunotherapies to address the challenges of unmet medical need diseases, today announced the first patient dosing inAustralia on Dec 30, 2024 for Phase 1 cl...
2025-01-03 01:43
2726
Fapon Biopharma Introduces FP008 at Biotech Showcase: A Safer and More Effective Immunotherapy for Refractory Cancers
SAN FRANCISCO, Jan. 2, 2025 /PRNewswire/ -- Fapon Biopharma, an innovator in developing therapeutic antibodies and fusion proteins, will present its latest breakthrough immunocytokine, FP008, onJan 14, 2025, at the Biotech Showcase investor conference, following J.P. Morgan Healthcare Week. This ...
2025-01-02 17:17
1711
FDA Grants Orphan Drug Designation to MicuRx's MRX-5 for NTM Infections
SHANGHAI, Jan. 1, 2025 /PRNewswire/ -- Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx"，688373.SH) announced that MRX-5, its self-developed anti-infection drug, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment ofnon-tuberculous myco...
2025-01-02 12:52
2604
CARsgen Announces the Initiation of an Investigator-Initiated Trial for an Allogeneic CD19/CD20 CAR-T Therapy
SHANGHAI, Dec. 31, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the initiation of an investigator-initiated trial (IIT) inChina for K...
2024-12-31 21:50
3545
Ractigen Therapeutics Founder Dr. Long-Cheng Li Awarded 2024 Life Science Ice Breaking Award
NANTONG and SUZHOU, China, Dec. 31, 2024 /PRNewswire/ -- Ractigen Therapeutics proudly announces that its Founder and CEO, Dr.Long-Cheng Li, has been honored with the 2024 Life Science Ice Breaking Award. This award, established by Mr. Cai Lei, a prominent ALS patient and advocate, along with his ...
2024-12-31 20:00
2753
CG MedTech and CGBIO Showcase Korea's Spine Surgery Excellence to Global Experts
SEOUL, South Korea, Dec. 31, 2024 /PRNewswire/ -- CG MedTech (f/k/a Innosys, CEO Ju Mi Chung), a leading Korean orthopedic implant research and manufacturing company, partnered withCGBIO to host the International Spine Endoscopy Training Course. The event welcomed 12 medical professionals from nin...
2024-12-31 20:00
2796
Ping An Health Supported the Official Release of the "Group Standards for Remote and Internet-Based Family Doctor Healthcare Services"
HONG KONG and SHANGHAI, Dec. 31, 2024 /PRNewswire/ -- With Ping An Healthcare and Technology Company Limited's ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) strategic support, and guidance from the General Practice Development Research Center of Peking Universit...
2024-12-31 15:26
4817
Duality Biologics Announces B7H4 ADC Milestone Achievement and License Exercise by BeiGene
SOMERSET, N.J., SHANGHAI and SUZHOU, China, Dec. 30, 2024 /PRNewswire/ -- Duality Biologics ("DualityBio") announced that, BeiGene. Ltd. has exercised its exclusive option for the B7H4 antibody-drug conjugate (ADC) DB1312/BG-C9074 from DualityBio, securing global development, manufacturing, and ...
2024-12-31 08:00
2417
I Peace manufactures 100 lines of GMP iPS Cells cumulatively
Proof of customer recognition of its quality and mass manufacturing capability
PALO ALTO, Calif., Dec. 30, 2024 /PRNewswire/ -- Leading GMP cell CDMO I
Peace, Inc. (https://ipeace.com/en/
2024-12-31 04:24
1853
Bridge Biotherapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SEONGNAM, South Korea and BOSTON, Dec. 30, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis and cancer, today announced that James Jungkue Lee, Founder and CEO of Bridge Biotherapeutics, will present ...
2024-12-30 23:00
2960
CARsgen Announces Positive Topline Results from China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T (Satri-cel)
SHANGHAI, Dec. 30, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the positive results from the pivotal Phase II clinical trial CT041-...
2024-12-30 21:50
2913
WuXi AppTec's Commitment to Sustainability Recognized by the Dow Jones Sustainability Indices (DJSI) for the Fourth Consecutive Year
SHANGHAI, Dec. 30, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that it has been recognized by the prestigious Dow Jones Sustainability Indices ...
2024-12-30 20:00
3119
Huadong Medicine Co., Ltd. and SynerK reached a strategic cooperation to jointly develop a novel siRNA drug SNK-2726
SUZHOU, China, Dec. 30, 2024 /PRNewswire/ -- Hangzhou Sino-US Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine"), a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), and SynerK PharmaTech (Suzhou) Co., Ltd. (hereinafter referred to as "SynerK") have reache...
2024-12-30 13:00
2108
Maypharm Unveils Revolutionary Hybrid Filler, Hyalmass Aqua-Exosome: The Future of Skin Hydration and Regeneration
* Introducing Hyaluronic Acid, Exosomes, and PDRN SEOUL, South Korea, Dec. 30, 2024 /PRNewswire/ -- Maypharm Co., Ltd., a leading innovator in medical and dermo-cosmetic products, proudly introduces the global launch of Hyalmass Aqua-Exosome, a groundbreaking hybrid mesotherapy filler designed ...
2024-12-30 13:00
3219
BMG Completed Acquisition of High-Quality Assets, Marking a New Chapter in Diversified Growth
CHENGDU, China, Dec. 27, 2024 /PRNewswire/ -- BGM Group Ltd. (Nasdaq: BGM) (the "Company" or "BGM"), a leading global pharmaceutical enterprise, today announced completion of the acquisition of the intelligent platform of AIX Inc. It marks BGM's official entry into the domains of AI intelligent t...
2024-12-27 22:30
8434
Matwings Technology Raised Series A Funding of Tens of Millions USD to Redefine Protein Design
'Beyond Structure, Predicting Function' SHANGHAI, Dec. 25, 2024 /PRNewswire/ -- Recently, Shanghai Matwings Technology Co., Ltd. ('Matwings'), a global leader in AI-driven protein design, announced the successful completion of Series A funding rounds, raising tens of millions of USD, led by Qimi...
2024-12-26 11:07
2111
Week's Top Stories
Most Reposted
Nine Years of Impact: JULO Disburses USD 1.7 Billion in Digital Financing Across Indonesia
[Picked up by 297 media titles]
2025-12-23 14:23
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 278 media titles]
2025-12-26 12:55ACEN completes transition to 100% renewable energy
[Picked up by 269 media titles]
2025-12-29 18:53CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 262 media titles]
2025-12-29 09:00
ChinaAMC launches Depository Receipts of two Chinese flagship ETFs in Thai exchange
[Picked up by 259 media titles]
2025-12-29 14:27Most Read
GreenTree Hospitality Group Ltd. Reports Third Quarter of 2025 Financial Results
2025-12-23 22:30
3754
Highway Holdings Plans to Acquire 51% of Regent-Feinbau Adermann GmbH
2025-12-23 20:00
3525
